As someone who’s seen Alzheimer’s up close, this research offers a glimmer of hope. Focused ultrasound could open new doors, literally, by safely clearing harmful plaques without drugs. It’s a step toward treatments that ease symptoms and protect memories. I’m hopeful for what this means for families like mine.

Alzheimer’s runs in my family, and I’ve seen its devastating impact firsthand. A groundbreaking study reveals a blood biomarker test with remarkable accuracy, offering a non-invasive, accessible way to diagnose Alzheimer’s early in primary and secondary care. This innovation could revolutionize care, providing timely interventions for millions affected worldwide

Donanemab, a monoclonal antibody targeting amyloid plaques, significantly slowed Alzheimer’s progression in a major trial. By preserving cognition and daily function, it offers new hope for early Alzheimer’s patients, despite some risks like amyloid-related imaging abnormalities.